Major contributions of AARDEX Group to HIV medication adherence monitoring and management

AUG-2018 : Amsterdam, 22nd International AIDS Conference: AARDEX Group presented

AUG-2018 : Amsterdam, 22nd International AIDS Conference: AARDEX Group presented the results of a 5-year successful project on HIV medication adherence management program, confirming the benefits of adherence feedback based on MEMS® technology. 

The implementation of this program in demanding low resource settings was made possible thought a grant from The Bill and Melinda Gates foundation. The HIV prevention program (PrEP) is implemented in various populations at risk for HIV across 3 African countries. It involves 1716 subjects recruited in Kenya (#1421), Senegal (#181) and Nigeria (#114). Download here the ePoster.

Once more, AARDEX Group confirms its leading contribution to monitor and manage HIV medication adherence by deploying its MEMS® technology in more than 70 HIV related projects, involving 20’000+ subjects across 70 countries on all continents.

MEMS, medAmigo and AARDEX are AARDEX Group registered marks.

Share This Post

You may also like...

Breaking News

Clinical trial failures: Are we counting the cost of poor adherence?

Clearly it is in no one’s interests for a clinical trial to fail. Whenever these high-stake activites are abandoned and drug development pathways are aborted, missed opportunities abound. Beyond the sponsor’s missed commercial opportunity, there are missed opportunities to advance